Our data implicate the NOTCH1/SNAI1/MEF2C signaling axis as a major determinant of TPC self-renewal and differentiation in ERMS, raising hope of therapeutically targeting this pathway in the future. The gene discussed is MEF2C; the disease is embryonal rhabdomyosarcoma.